Consumption of gluten with gluten-degrading enzyme by celiac patients: A pilot-study Full Text
World Journal of Gastroenterology,  Clinical Article

Tack GJ et al. – The study aims to assesses the safety and efficacy of Aspergillus niger prolyl endoprotease (AN–PEP) to mitigate the immunogenic effects of gluten in celiac patients. AN–PEP appears to be well tolerated. However, the primary endpoint was not met due to lack of clinical deterioration upon placebo, impeding an effect of AN–PEP.

Methods

  • Patients with initial diagnosis of celiac disease as confirmed by positive serology with subtotal or total villous atrophy on duodenal biopsies who adhere to a strict gluten-free diet (GFD) resulting in normalised antibodies and mucosal healing classified as Marsh 0 or I were included.
  • In a randomised double-blind placebo-controlled pilot study, patients consumed toast (approximately 7 g/d gluten) with AN-PEP for 2 wk (safety phase).
  • After a 2-wk washout period with adherence of the usual GFD, 14 patients were randomised to gluten intake with either AN-PEP or placebo for 2 wk (efficacy phase).
  • Measurements at baseline included complaints, quality-of-life, serum antibodies, immunophenotyping of T-cells and duodenal mucosa immunohistology.
  • Furthermore, serum and quality of life questionnaires were collected during and after the safety, washout and efficacy phase.
  • Duodenal biopsies were collected after the safety phase and after the efficacy phase.
  • A change in histological evaluation according to the modified Marsh classification was the primary endpoint.

Results

  • In total, 16 adults were enrolled in the study.
  • No serious adverse events occurred during the trial and no patients withdrew during the trial.
  • The mean score for the gastrointestinal subcategory of the celiac disease quality (CDQ) was relatively high throughout the study, indicating that AN-PEP was well tolerated.
  • In the efficacy phase, the CDQ scores of patients consuming gluten with placebo or gluten with AN-PEP did not significantly deteriorate and moreover no differences between the groups were observed.
  • During the efficacy phase, neither the placebo nor the AN-PEP group developed significant antibody titers.
  • The IgA-EM concentrations remained negative in both groups.
  • Two patients were excluded from entering the efficacy phase as their mucosa showed an increase of two Marsh steps after the safety phase, yet with undetectable serum antibodies, while 14 patients were considered histologically stable on gluten with AN-PEP.
  • Also after the efficacy phase, no significant deterioration was observed regarding immunohistological and flow cytometric evaluation in the group consuming placebo compared to the group receiving AN-PEP.
  • Furthermore, IgA-tTG deposit staining increased after 2 wk of gluten compared to baseline in four out of seven patients on placebo.
  • In the seven patients receiving AN-PEP, one patient showed increased and one showed decreased IgA-tTG deposits.

Please login or register to follow this author.
► Click here to access Full Text, PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

Your Unread Messages in Gastroenterology

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Gastroenterology Articles

1 Screening prior to biological therapy in Crohn's disease: Adherence to guidelines and prevalence of infections. Results from a multicentre retrospective study Digestive and Liver Diseases, August 4, 2014    Clinical Article

2 The probiotic VSL#3 has anti-inflammatory effects and could reduce endoscopic recurrence following surgery for Crohn's disease Clinical Gastroenterology and Hepatology , November 7, 2014    Clinical Article

3 Systematic review: new serological markers (anti-glycan, anti-GP2, anti-GM-CSF Ab) in the prediction of IBD patient outcomes Autoimmunity Reviews, November 19, 2014    Evidence Based Medicine    Review Article

4 Higher vitamin D serum concentration increases health related quality of life in patients with inflammatory bowel diseases Full Text World Journal of Gastroenterology, November 17, 2014    Free full text    Clinical Article

5 Magnetic resonance enterocolonography is highly detectable of erosion and redness in intestinal mucosa of patients with Crohn's disease Journal of Gastroenterology and Hepatology, November 20, 2014    Clinical Article

6 Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis Clinical Gastroenterology and Hepatology , June 25, 2014    Evidence Based Medicine    Clinical Article

7 Predictors of response to steroid therapy for eosinophilic esophagitis and treatment of steroid-refractory patients Clinical Gastroenterology and Hepatology , September 19, 2014    Clinical Article

8 Re-treatment of chronic hepatitis C virus genotype 1 infection after relapse: an open-label pilot study Annals of Internal Medicine, November 11, 2014    Evidence Based Medicine    Clinical Article

9 Clinical utility and diagnostic accuracy of faecal calprotectin for IBD at first presentation to gastroenterology services in adults aged 16-50years Journal of Crohn's and Colitis, September 8, 2014    Clinical Article

10 Lactulose vs polyethylene glycol 3350-electrolyte solution for treatment of overt hepatic encephalopathy: the help randomized clinical trial JAMA Internal Medicine, October 13, 2014    Evidence Based Medicine    Clinical Article

11 The use of sirolimus (rapamycin) in the management of refractory inflammatory bowel disease in children Journal of Crohn's and Colitis, November 3, 2014    Clinical Article

12 The impact of timing and duration of thiopurine treatment on colectomy in ulcerative colitis: A national population-based study of incident cases between 1989–2009 Alimentary Pharmacology and Therapeutics, November 12, 2014    Clinical Article

13 Consumption of garlic and risk of colorectal cancer: An updated meta-analysis of prospective studies Full Text World Journal of Gastroenterology, November 18, 2014    Free full text    Evidence Based Medicine

14 Association between serrated polyps and the risk of synchronous advanced colorectal neoplasia in average-risk individuals Alimentary Pharmacology and Therapeutics, October 27, 2014    Clinical Article

15 Idiopathic inflammatory demyelinating disease of the central nervous system in patients with inflammatory bowel disease: retrospective analysis of 9095 patients Alimentary Pharmacology and Therapeutics, November 4, 2014    Clinical Article

16 Timing of rebleeding in high-risk peptic ulcer bleeding after successful hemostasis: A systematic review Canadian Journal of Gastroenterology, November 12, 2014    Review Article

17 Risk of lymphoma in patients with inflammatory bowel disease treated with azathioprine and 6-mercaptopurine: a meta-analysis Clinical Gastroenterology and Hepatology , September 25, 2014    Clinical Article

18 The relationship between infliximab concentrations, antibodies to infliximab and disease activity in Crohn's disease Gut, November 13, 2014    Clinical Article

19 High-dose dual therapy is superior to standard first-line or rescue therapy for Helicobacter pylori infection Clinical Gastroenterology and Hepatology , November 21, 2014    Clinical Article

20 Risk of upper gastrointestinal bleeding from different drug combinations Gastroenterology, October 13, 2014    Clinical Article

Indexed Journals in Gastroenterology: Gastroenterology, American Journal of Gastroenterology, Gutmore